David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$751M |
| 2 |
Advanced Micro Devices
AMD
|
+$751M |
| 3 |
Micron Technology
MU
|
+$426M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$363M |
| 5 |
ExxonMobil
XOM
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$546M |
| 2 |
ATVI
Activision Blizzard
ATVI
|
+$485M |
| 3 |
VMW
VMware, Inc
VMW
|
+$393M |
| 4 |
Microsoft
MSFT
|
+$336M |
| 5 |
UnitedHealth
UNH
|
+$303M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.03% |
| 2 | Consumer Discretionary | 9.51% |
| 3 | Healthcare | 5.77% |
| 4 | Financials | 5.47% |
| 5 | Communication Services | 4.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2026
CALL
Levi Strauss
LEVI
$8.25B
| $3.68M | ﹤0.01% |
222,400
| – | – |
|
2027
Clearwater Paper
CLW
$344M
| $3.68M | ﹤0.01% |
101,807
+51,066
| +101% | +$1.83M |
|
2028
Kodiak Sciences
KOD
$2.47B
| $3.68M | ﹤0.01% |
1,208,973
+212,840
| +21% | +$473K |
|
2029
PUT
Teva Pharmaceuticals
TEVA
$44.2B
| $3.67M | ﹤0.01% |
351,600
-120,000
| -25% | -$1.12M |
|
2030
Vanguard Morningstar Total Stock Market ETF
VTI
$685B
| $3.67M | ﹤0.01% |
+15,469
| New | +$3.42M |
|
2031
Zions Bancorporation
ZION
$9.97B
| $3.67M | ﹤0.01% |
83,616
+69,556
| +495% | +$2.51M |
|
2032
Cummins
CMI
$79.6B
| $3.65M | ﹤0.01% |
15,245
+3,069
| +25% | +$698K |
|
2033
Antero Midstream
AM
$10.7B
| $3.65M | ﹤0.01% |
291,343
+43,182
| +17% | +$544K |
|
2034
Vericel Corp
VCEL
$2.17B
| $3.65M | ﹤0.01% |
102,439
-76,750
| -43% | -$2.67M |
|
2035
SAP
SAP
$244B
| $3.64M | ﹤0.01% |
+23,551
| New | +$3.41M |
|
2036
Toyota
TM
$227B
| $3.64M | ﹤0.01% |
+19,844
| New | +$3.62M |
|
2037
Olin
OLN
$2B
| $3.63M | ﹤0.01% |
67,276
-16,400
| -20% | -$785K |
|
|
ESPR
2038
DELISTED
Esperion Therapeutics
ESPR
| $3.63M | ﹤0.01% |
+1,213,203
| New | +$1.57M |
|
2039
W.R. Berkley
WRB
$25.5B
| $3.63M | ﹤0.01% |
76,893
-270,752
| -78% | -$12.3M |
|
|
RVNC
2040
DELISTED
Revance Therapeutics, Inc.
RVNC
| $3.62M | ﹤0.01% |
411,750
-370,266
| -47% | -$3.03M |
|
2041
PUT
TD Synnex
SNX
$20.4B
| $3.62M | ﹤0.01% |
+33,600
| New | +$3.3M |
|
2042
Madrigal Pharmaceuticals
MDGL
$12.5B
| $3.61M | ﹤0.01% |
15,622
+9,708
| +164% | +$1.7M |
|
2043
Microvast
MVST
$295M
| $3.61M | ﹤0.01% |
2,580,479
+428,093
| +20% | +$574K |
|
2044
Gevo
GEVO
$408M
| $3.61M | ﹤0.01% |
3,107,884
-230,299
| -7% | -$263K |
|
2045
Alto Ingredients
ALTO
$316M
| $3.6M | ﹤0.01% |
1,354,886
+497,854
| +58% | +$1.59M |
|
2046
Camden Property Trust
CPT
$12.5B
| $3.59M | ﹤0.01% |
36,181
-76,128
| -68% | -$7.05M |
|
2047
Jefferies Financial Group
JEF
$12.2B
| $3.58M | ﹤0.01% |
88,715
-140,679
| -61% | -$4.98M |
|
|
HCP
2048
DELISTED
HashiCorp, Inc. Class A Common Stock
HCP
| $3.58M | ﹤0.01% |
151,520
-124,414
| -45% | -$2.7M |
|
2049
Exelon
EXC
$45.8B
| $3.58M | ﹤0.01% |
99,763
-49,849
| -33% | -$1.92M |
|
|
SEE
2050
PUT
DELISTED
Sealed Air
SEE
| $3.58M | ﹤0.01% |
98,000
-23,900
| -20% | -$784K |
|
Similar funds
David Shaw's Q4 2023 Portfolio in Review
As of Q4 2023, David Shaw held 4,806 positions worth $114B, up 19% from $95.8B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
David Shaw's Q4 2023 filing shows 575 new, 1,549 increased, 1,464 reduced and 527 closed positions. Its largest new stake was iShares iBoxx $ High Yield Corporate Bond ETF: 2,424,593 shares worth $188M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $546M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 17% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- David Shaw's largest Q4 2023 buy was iShares iBoxx $ High Yield Corporate Bond ETF: 2,424,593 shares worth $188M.
- David Shaw added most to Netflix in Q4 2023, an estimated $751M increase.
- David Shaw's biggest Q4 2023 reduction was Microsoft, cutting an estimated $336M.
- David Shaw fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $546M.
- David Shaw's ten largest holdings make up 12% of its $114B portfolio in Q4 2023.
- David Shaw opened 575 new positions and closed 527 in Q4 2023.
- David Shaw's portfolio value rose 19% quarter-over-quarter to $114B.
Based on D.E. Shaw & Co's 13F filing for Q4 2023, filed 14 Feb 2024.